Objective: To investigate the chemical constituents from the fruit of Euscaphis fukienensis. Methods: The chemical constituents were isolated and purified by silica gel, Sephadex LH-20 column chromatography and liquid phase preparation, and the structure were elucidated on the basis of nuclear magnetic technique. Results: Eighteen compounds were obtained from the fruit of E. fukienensis, which were named as betulinic acid (1), tetraketide (2), β-sitosterol (3), oleanolic acid (4), pomolic acid (5). β-amyrin (6), gallic acid (7), 3,3’-dimethoxy ellagic acid (8), quercetin (9), kaempferol (10), isorhamnetin (11), 2-epitormentic acid (12), 3,3’,4’-trimethoxy ellagic acid (13), 1-oxosiaresinolic acid (14), 2-oxopomolic acid (15), momordic acid (16), ursolic acid (17), isorhamnetin-3-O-rutinoside (18). Conclusion: Compounds 6, 11-15 and 18 are isolated from E. fukienensis for the first time, and compounds 13-15 are isolated from the genus Euscaphis for the first time.

Background:Transcranial alternating current stimulation (tACS) offers a new approach for adult patients with major depressive disorder (MDD).The study is to evaluate the efficacy and safety of tACS treating MDD.Methods:This is an 8-week,double-blind,randomized,placebo-controlled study.Ninety-two drug-naive patients with MDD aged 18 to 65 years will receive 20 daily 40-min,77.5-Hz,15-mA sessions of active or sham tACS targeting the forehead and both mastoid areas on weekdays for 4 consecutive weeks (week 4),following a 4-week observation period (week 8).The primary outcome is the remission rate defined as the 17-item Hamilton depression rating scale (HDRS-17) score ≤7 at week 8.Secondary outcomes are the rates of response at weeks 4 and 8 and rate of remission at week 4 based on HDRS-17,the proportion of participants having improvement in the clinical global impression-improvement,the change in HDRS-17 score (range,0-52,with higher scores indicating more depression) over the study,and variations of brain imaging and neurocognition from baseline to week 4.Safety will be assessed by vital signs at weeks 4 and 8,and adverse events will be collected during the entire study.Discussion:The tACS applied in this trial may have treatment effects on MDD with minimal side effects.